A phase II study of phenesterin (NSC-104469)

Area of Science:

• Oncology
• Pharmacology

Background:

• Phenesterin is an investigational chemotherapeutic agent.
• Evaluating treatment efficacy and toxicity is crucial for drug development.

Purpose of the Study:

• To assess the efficacy and toxicity of Phenesterin in cancer patients.
• To compare daily versus intermittent dosing regimens.

Main Methods:

• A clinical trial involving 222 patients with various cancers.
• Patients received Phenesterin via daily or intermittent schedules.
• Response rates and toxicity were monitored.

Main Results:

• Moderate toxicity was observed across both dosing regimens.
• Breast cancer patients (largest group) showed a 10% response rate.
• Ovarian cancer patients demonstrated a significantly higher response rate of 36%.

Conclusions:

• Phenesterin exhibits moderate toxicity.
• The drug shows promising efficacy in ovarian cancer patients.
• Further investigation into Phenesterin for ovarian cancer is recommended.